Conclusions:
The use of an everolimus-eluting stent to provide straightline inflow to the foot in patients with rest pain or ulceration and infrapopliteal disease can provide acceptable 3-year limb salvage results.
Summary: This is a prospective, single-center registry study of patients with rest pain or minor ischemic ulceration and with distal popliteal and proximal tibial artery occlusive lesions up to 10 cm in length. The treatment was revascularization using the Xience-Prime EverolimusEluting Stent of the target greater than 70% BTK denovo lesion or restenosis consisting of 20 to 100 mm in length with a vessel diameter of 2 to 3.5 mm. Ultimately, one tibial or peroneal artery must supply in-line flow to the pedal arteries related to the ischemic area of the foot. Exclusion criteria were aneurysmal disease, prior surgery, acute thrombosis, nonatherosclerotic disease, or noncompliance with antiplatelet therapy. The primary end point was primary patency defined as freedom from restenosis of target vessel (peak systolic velocity ratio $ 2.4 on duplex imaging). Secondary end points were amputation-free survival (freedom from above ankle amputation of index limb), clinical success (Rutherford-Becker classification improvement 1 or more), wound healing (complete), immediate success, target lesion revascularization (TLR) rate due to restenosis, CLI recurrence, and the cumulative rate of freedom from death and major amputation, secondary patency, and survival rates. All end points were evaluated at 1, 2, and 3 years. Some caveats of the study: femoropopliteal disease was treated at the same time with angioplasty with provisional stenting, predilation of the target lesion with a shorter and smaller balloon was allowed, the drug-coated stent must cover the entire lesion with 5-mm overlap to normal artery above and below. Follow-up was physical examination and duplex imaging with angiography preformed for duplex demonstrated restenosis or CLI symptoms. Of 423 patients with CLI treated during the 3 year recruitment (2011) (2012) (2013) (2014) , 122 patients met study criteria. The average age was 70.9, 63.9% were male, and 60.6% had ulceration. The mean lesion length was 52.7 mm (20-100 mm) with most having extensive calcification (65.2%). The BTK was occluded in 68%. Immediate success was 100%. One and two stents were used in 60.6% and 29.5% of cases respectively. Twelve cases required three stents. Five procedural complications included four hematomas treated conservatively and one pseudoaneurysm requiring surgical repair. Patients completing follow-up were 88 at 1 year, 47 at 2 years, and 34 at 3 years. Eight patients were lost to follow-up (six at 1 year, two at 3 year). Twenty-six patients died during the 3 years due to cardiac disease (n ¼ 15) and respiratory disease (n ¼ 5), and six died from cancer. Fourteen patients required secondary angiography of the target limb: 10 required target lesion revascularization and four a new intervention. The 1-and 2/3-year primary patency rates were 88.9% and 80.1%, respectively. The survival, major amputation-free survival, and freedom from target lesion revascularization rates were: 88.1%, 93%, and 91.5% at 1-year follow-up; 75.7%, 89.3%, and 85.1% at 2-year follow-up; and 70.4%, 89.3%, and 85.1% at 3-year follow-up. The secondary patency rate was 92.2% at 1 year and 85% at 2 and 3 years. The freedom from cumulative major amputation/death rate was 82.7% at 1-year follow-up and 64.3% at 2-and 3-year follow-up, respectively. Diabetes had no significant influence on the results. Primary patency influenced major amputation rate, which was a 60% amputation rate in patients with no target artery patency vs 5.4% in patients with target patency (P ¼ .022). At 1-year follow-up, 78 (88.6%) of 88 patients improved 1 or more of their Rutherford-Becker category, and 48 (80%) of 69 patients had wound healing (maintained at 85.3% in the 34 patients at the 3-year follow-up).
Comments: This single-center study provides some data to suggest that distal popliteal/proximal tibial drug-eluting stent placement can provide acceptable midterm limb salvage without excessive reintervention rates in patients with rest pain and minor ulcerations. Those with more extensive ischemia where mild/moderate improvements in perfusion might not allow salvage are not studied. It is unfortunate that no estimation of improved distal perfusion (ABI) is provided to determine the degree of improved perfusion for comparison over time. Most investigators would have provided patient outcomes (limb salvage) as primary outcome rather than the surrogate primary patent of the target lesion restenosis.
Summary: This 8-year (ending in December 2013) single-institution retrospective study of patients treated with endovascular aortic repair (EVAR) for standard (in compliance with instructions for use) infrarenal aneurysmal disease provided the data used to determine if statins had an effect on AAA sac regression. To eliminate the effect of graft type, only patients treated with the EXCLUDER device were included. Any patient whose postintervention imaging demonstrated with a type I, II, or III endoleak, stent graft migration or failure, rupture, surgical conversion, or endotension was excluded from analysis. It is unclear as to how the authors define endotension. The medical records of 344 patients who underwent EVAR with the EXCLUDER were identified. Exclusion criteria eliminated 230 patients, leaving 109 for further analysis, of which 64 received statins and 45 did not. Prior to EVAR, 56 patients were receiving statins. At baseline, the statin treated group had more coronary artery disease (CAD) (62.5% vs 35.6%; P ¼ .006) and hyperlipidemia (100% vs 26.7%; P ¼ .001) and were more likely to be treated with a b-blocker (57.8% vs 31.3%; P ¼ .006). The difference between average AAA maximal diameter, neck diameter, neck length, and mean aortic neck angle were not statistically different. Large diameter AAA ($60 mm) were more evident in the statin group (34.4% vs 15.6%; P ¼ .029). CT angiography was scheduled at 1, 6, 12 months, and then yearly. The primary end point was AAA sac regression (defined as 5 mm sac shrinkage from prior EVAR to any post-EVAR CT angiogram) at 1 and 2 years. The secondary end points were incidence of sac retraction, stable sac size, and sac enlargement (aneurysmal growth). AAA sac growth was defined as a sac $5 mm, while a stable sac was a diameter between e5 to +5 mm prerepair to any postrepair CT angiogram. Sac retraction could be a change from large ($60 mm) to medium (5-5.9 mm) or small sac size (<5 mm) or a diameter less than 3.5 cm. The no-statin group had higher rates of AAA sac regression than the statin group at 1 year (66.7% vs 45.3%; P ¼ .028) but no statistical difference was seen between the two groups at 2 years (66.7% vs 57.8%; P ¼ .350). The difference between the changes in maximum AAA diameter was significant between groups at 1 year (no-statin group vs statin group, À7.9 mm 6 8.3 vs À4.9 mm 6 5.9 mm; P ¼.041), but the difference did not reach statistical significance at 2 years (À10.0 mm 6 10.1 vs À8.0 mm 6 9.6; P ¼ .306). Statin therapy was not associated with AAA sac regression on univariate (P ¼ .351) and multivariate analyses (odds ratio, 0.617; 95% confidence interval, 0.215-1.772; P ¼ .369). Sac retraction and stable sac size followed the same trends being significant at one but not at two years. In patients with a large AAA, the two groups showed no difference in the incidence of AAA sac regression at 1 year (no-statin group, n ¼ 5 Comments: The exclusion of endoleaks and endotension makes the study cleaner for analysis but these factors are generally considered the reasons for sac growth and, therefore, this study eliminates a potentially important group from analysis. Since the statin-treated group had a greater percentage of patients with CAD, hyperlipidemia, and large size AAAs, the nonstatistical effect of statins may actually suggest a beneficial effect over time in a highly disadvantaged group of patients. It does not provide data to suggest that patients without these risks factors are aided by the addition of statins. This study presents a different spin on the use of medical therapy following EVAR, which was reported in the Journal of Vascular Surgery, demonstrating that b-blockers had no effect on Conclusions: Gastroduodenal artery and PDA aneurysms present most commonly with pain or bleeding, and should be considered for repair regardless of size. Aneurysm exclusion is safely and effectively achieved with endovascular coiling. Although associated celiac artery stenosis is found in the majority of cases, celiac revascularization might not be necessary.
Summary: The hypothesis of this 9-year single-center retrospective study is that coil embolization without celiac artery revascularization is adequate treatment for gastroduodenal artery (GDA) or pancreaticoduodenal artery (PDA) aneurysms with associated celiac artery stenosis. Search of a university deidentified database yielded 225 patients with aneurysms of other visceral arteries (code 442.84), of which 20 fit the criteria for this study. Eleven patients were female and average age was 61.5 years (range, 35-85 years). Sixteen patients had PDA aneurysms (15 inferior PDA and one superior PDA), and four GDA aneurysms. Only three were asymptomatic when discovered, 9 presented with rupture (7 PDA, 2 GDA) and 8 with pain. Eight of the nine ruptures demonstrated a contained retroperitoneal hematoma and one ruptured inferior PDA aneurysm presented with hypotension, was successful resuscitated and underwent aneurysm embolization. The mean size of the aneurysm in the 15 where data were available averaged 16 mm in rupture cases, 19 mm in those with pain only, and 16 mm in the asymptomatic patients. Associated celiac artery stenosis > 60% was noted in 14, complete celiac artery occlusion in 1, and 2 patients had a >80% of both the celiac and superior mesenteric arteries. Three did not have an associated stenosis of either artery. There is no mention made of prior pancreatitis but three had a prior cholecystectomy. Thirteen had successful coil embolization of the aneurysm, with only one undergoing a celiac bypass in delayed fashion (in a then asymptomatic patient) and the others having no hepatic or mesenteric artery symptoms acutely or during a median 12-month follow-up. Three patents underwent open ligation with celiac artery bypass (n ¼ 2) or celiac and superior mesenteric artery bypass (n ¼ 1). Four patients had no intervention, 2 were asymptomatic, 1 deemed not to be a surgical candidate, and 1 resolved discomfort within hours of hospitalization. All 20 patients survived to discharge and had no clinical issues for a median 10 months (range, 2-200 months). Based on the eight patients with coil embolization and no ill effect, the authors postulate that alternative collaterization must be adequate in most patients with isolated celiac artery stenosis to not require celiac revascularization. In the discussion, they add that revascularization should be considered in patients with both celiac and supermesenteric artery stenosis, but it is unclear if the data support or contradict his impression. Recurrence of peripancreatic aneurysmal disease due to continued increased collateral flow when the celiac artery is not revascularized was not found to be a common in this study, but it is unclear in the text how frequently imaging was undertaken to prove this impression.
Comments: The clinical question regarding the need for celiac artery revascularization for stenosis at the time of or subsequent to GDA or PDA coil embolization to prevent liver ischemia or new peripancreatic aneurysmal disease is not clear. This study's goal was to provide some clarity in this regard. It does confirm some of the impressions regarding the clinical presentation of these aneurysms and the associated patient demographics. It does confirm the fact that in the acute situation, aneurysmal embolization (occlusion) does prevent continued bleeding and celiac stenosis does not require immediate repair since the liver was not damaged based on clinical parameters. However, since the celiac disease is only of the stenotic variety in most cases, continued celiac flow may be sufficient to prevent ischemia in its own right without recruitment of other collateral routes. Since there is no clear mention of diagnostic imaging on follow-up, it is unclear whether conclusions regarding development of new aneurysms has any validity. The clinical course seems to be benign in most cases.
